Top editors picks!

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

Apogee’s IL-13 APG777 Could Challenge Top Contenders In Autoimmune Disorder Targeting Space

To Get Wet-AMD Gene Therapy To Finish Line 4DMT Reduces Workforce By 25%

Nektar’s Rezpeg Hopes Revived After Latest Atopic Dermatitis Treatment Data

MoonLake Sought Out For By Merck For $3 Billion To Add Sonelokimab To Arsenal, FT Reports

Kymera Achieves Positive STAT6 Protein Degrader Results In Healthy Volunteer Study

Summit Reports Mixed Ivonescimab Data But Path Forward Might Remain

iTeos Doubles Down On Strategic Alternatives After TIGIT Failures

Amazing Survival Feat In Solid Tumors Achieved With Merus Petosemtamab

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

Rhythm Pharmaceuticals Scores A Win For Obesity Disorder Caused By Impairment Of The Brain

Beigene’s Anti-TIGIT Trial Closure Doesn’t Bode Well For This Drug Class Going Forward

Sangamo Gets Lifeline From Eli Lilly In $1.4 Billion Dollar Deal For Proprietary AAV Capsid

Second FDA Rejection Of Aldeyra Therapeutics But Hope Remains With Two Upcoming Events

Latest Corcept Data Could Lead To New Standard Of Care Option for Platinum-Resistant Ovarian Cancer Patients

Scroll to Top